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Background: We recently reported reduction in the STEMI rate in the United State.
We thought that this could lead to reduction in the rate of cardiogenic shock over the
years. In this study we evaluated the nation wide trend in the incidence of cardiogenic
shock in the United State using a Large Database.
Methods: The Nationwide Inpatient Sample (NIS) database was utilized to calculate
the age-adjusted incident rate of cardiogenic shock from 1996 to 2006 based on ICD-
9 of 785.51.
Results: A total population of 29,190,701 patients were available between 1996-2006.
We found that the incidence of cardiogenic shock has not been changed over the last
10 years. The age-adjusted rate for cardiogenic shock was 8.1 per 100,000 in 19996
which remained steady with an incidence of 9.01 per 100.000 in 2006. Lack of decline
in the incidence of cardiogenic shock was persistent across different race or gender. In
comparison to male, women had lower total incidence of age adjusted incidence of
cardiogenic shock.
Conclusion: Despite advancement in the treatment of cardiovascular disease, the
incidence of cardiogenic shock has not been changed over the last 10 years.
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Background: Loss of systolic apical rotation is associated with left ventricular (LV)
remodeling and systolic dysfunction. Surgical ventricular reconstruction (SVR) has
been shown benefit to patients with large LV anteroapical myocardial infarction (MI).
Currently, application of SVR requires ventriculotomy and cardio-pulmonary support.
In this study, we evaluated the long-term effect of minimally invasive, off-pump,
epicardial catheter-based ventricular reconstruction (ECVR) approach on the LV
rotation and global and regional function in an ovine model of LV anteroapical
aneurysm.
Methods: LV aneurysms were induced by percutaneous coil embolization of LAD. 8
wks after occlusion, ECVR was performed via left thoractomy in 8 sheep. The scar
was excluded by placing anchor pairs between the LV epicardial anterior wall and the
right ventricular side of the septum under fluoroscopic guidance. LV rotation and
performances were evaluated by echo before, after device implantation and at 6 wks
follow up.
Results: ECVR was completed in all animals without any complications. Immediately
after the device implantation, LV rotation increased significantly; ejection fraction (EF)
increased 17%; LV end-diastolic (EDV) and end-systolic volume (ESV) significantly
decreased 22% and 40% respectively. Stroke volume was preserved. The most
pronounced circumferential strain improvement was found in the anteroseptal wall
(from -0.3% to -8%, p<0.03). These effects were maintained at least 6 wks after device
implantation and no trend toward re-dilation.
Mean ±SD, *P<0.05 vs. pre-device
Conclusion: ECVR on the off pump beating heart can restore LV rotation and systolic
strains and reverse LV remodeling in an anteroapical aneurysm ovine model.
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Background: Myocardial Infarction (MI) is a common finding in patients with Heart
Failure (HF). Remote wireless monitoring of pulmonary artery pressure (PAP) was
shown to be effective in reducing Heart Failure Related (HFR) hospitalizations. We
reviewed the clinical course of patients in the CHAMPION trial with or without a
history of MI to determine if wireless hemodynamic monitoring of PAP had an impact
on clinical outcomes.
Methods: The CHAMPION trial is a prospective, randomized trial that enrolled 550
NYHA III HF patients. The sensor was implanted in conjunction with a RHC using
standard OTW techniques. For the treatment group, specific recommendations were
made regarding the management of intracardiac filling pressures, including guidelines
for neurohormonal, diuretic, and vasodilator medications. The control group received
standard of care as determined by each site’s investigators.
Results: HFR hospitalizations were analyzed using a negative binomial regression
methodology. There were 271 patients (134 treatment and 137 control) with a history
of MI versus 279 (136 treatment and 143 control) with no history of MI. For patients
with a history of MI, the treatment group had 46 HFR hospitalizations at 6 months
compared to 67 in control patients, a relative risk reduction (RRR) of 29.8% (p =
0.004). For patients without a history of MI, the treatment group had 38 HFR
Hospitalizations at 6 months versus 53 in the control group for a RRR of 25.3%
(p=0.016). Over the full duration of blinded follow-up (average 15 months), patients
with or without a history of MI experienced RRR of 46.3% (p<0.001) and 22.9%
(p=0.021).
Conclusion: Utilizing remote PAP data in the treatment group lead to a similar
reduction in HFR hospitalizations in patients with or without a history of MI. Further
study of the utility of remote hemodynamic monitoring is warranted in patients with
or without a history of MI to determine optimal drug and device therapy in reducing
HFR hospitalizations in NYHA III patients.
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Background: The CircuLite® Synergy® Pocket Micro-pump has been used in humans
for partial circulatory support. The system is surgically implanted into the left atrium
(LA) via mini-thoracotomy. In this study, we aimed to demonstrate the feasibility of
percutaneous delivery of the inflow cannula of the micro-pump through transseptal
access from the external jugular vein into the LA in a swine model.
Methods: Under fluoroscopic and intra-cardiac echo (ICE) guidance, LA access was
achieved via transseptal puncture in 6 healthy pigs. Superior access was created via
the right external jugular vein with a custom venous introducer. Through this
introducer, the CircuLite transseptal cannula system was advanced and anchored onto
the LA septum. The proximal end of the cannula was attached to the Synergy micro-
pump; the micro-pump outflow graft was connected to the right common carotid artery
by end-to-side anastomosis. A pocket was created for the pump within the neck. Follow
up was conducted at 1 (n=2), 2 (n=2) and 4 wks (n=2) after implantation.
Results: No peri-procedural complications related to the implantation of the device
were observed. The average duration to deliver the cannula was 36 ± 8 min. The micro-
pump speed was maintained at 22,000 rpm (~2.0L/min) and the animals were supported
between 1 and 4 wks with no cardiac adverse events. Blood tests for plasma free
hemoglobin confirmed the absence of hemolysis and generally remained below the
clinically relevant limit of 40mg/dl. Histology evaluation demonstrated properly
deployed of the inflow cannula in all animals. From 2 to 4wks, the anchors showed
complete endothelialization and healing with no surface thrombosis.
Conclusion: The percutaneous implantation of the transseptal inflow cannula of the
CircuLite Synergy pump via a superior access is feasible and safe in the porcine model.
This method of delivery represents a much less invasive alternative to the current
surgical implant and establishes the tools, techniques and viability of implanting such
a circulatory support device percutaneously in humans.
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